Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25663994 | 1.00 | TSHR (0.40) | TSHRL3MBTL1CHRM3SLC6A9MAPK1 | |
| SCHEMBL25769664 | 1.00 | TSHR (0.40) | TSHRL3MBTL1CHRM3SLC6A9MAPK1 | |
| SCHEMBL17207528 | 0.94 | TSHR (0.45) | TSHRSLC6A9MAPK1TDP1ALDH1A1 | |
| SCHEMBL26313200 | 0.84 | L3MBTL1 (0.40) | TSHRL3MBTL1CHRM3HTTALDH1A1 | |
| SCHEMBL12718165 | 0.84 | L3MBTL1 (0.40) | TSHRL3MBTL1CHRM3HTTALDH1A1 | |
| SCHEMBL24503573 | 0.84 | L3MBTL1 (0.36) | TSHRL3MBTL1SLC6A9MAPK1HTT | |
| SCHEMBL12718168 | 0.84 | L3MBTL1 (0.40) | TSHRL3MBTL1CHRM3HTTALDH1A1 | |
| SCHEMBL9892991 | 0.84 | HTT (0.37) | TSHRL3MBTL1SLC6A9MAPK1HTT | |
| SCHEMBL10808055 | 0.83 | CHRM3 (0.38) | L3MBTL1CHRM3HTTKDM4EPIK3CD | |
| SCHEMBL21870608 | 0.83 | CHRM3 (0.38) | L3MBTL1CHRM3HTTKDM4EPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20090137824-A1 | METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES | PHOENIX CHEMICALS LTD (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20080281106-A1 | Process for the Production of Asymmetric Transformation Catalysts | PHOENIX CHEMICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | TSHR 2425/4885L3MBTL1 2141/4885CHRM3 4038/4885 |
| US-20080281106-A1 | Process for the Production of Asymmetric Transformation Catalysts | OXSR1, OXGR1, OSR1 | TSHR 101/4885L3MBTL1 1297/4885CHRM3 538/4885 |
| US-20090137824-A1 | METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES | POLL, ZNF207, ZC3HAV1L | TSHR 1003/4885L3MBTL1 377/4885CHRM3 639/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | TSHR 3784/4885L3MBTL1 669/4885CHRM3 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.